Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2016

01-08-2016 | Review Article

Review: circulating tumor cells in the practice of breast cancer oncology

Authors: R. Ramos-Medina, F. Moreno, S. Lopez-Tarruella, M. del Monte-Millán, I. Márquez-Rodas, E. Durán, Y. Jerez, J. A. Garcia-Saenz, I. Ocaña, S. Andrés, T. Massarrah, M. González-Rivera, M. Martin

Published in: Clinical and Translational Oncology | Issue 8/2016

Login to get access

Abstract

The primary cause of tumor-related death in breast cancer is still represented by distant metastasization. The dissemination of tumor cells from the primary tumor to distant sites through bloodstream cannot be early detected by standard imaging methods. Circulating tumor cells (CTCs) play a major role in the metastatic spread of breast cancer. Different analytical systems for CTCs isolation and detection have been developed and novel areas of research are directed towards developing assays for CTCs molecular characterization. This review describes the current state of art on CTCs detection techniques and the present and future clinical implications of CTCs enumeration and characterization.
Literature
1.
Friel AM, Corcoran C, Crown J, O’Driscoll L. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat. 2010;123:613–25.CrossRefPubMed
2.
Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013;88:338–56.CrossRefPubMed
3.
4.
Broersen LHA, van Pelt GW, Tollenaar RAEM, Mesker WE. Clinical application of circulating tumor cells in breast cancer. Cell Oncol Dordr. 2014;37:9–15.CrossRefPubMed
5.
Esmaeilsabzali H, Beischlag TV, Cox ME, Parameswaran AM, Park EJ. Detection and isolation of circulating tumor cells: principles and methods. Biotechnol Adv. 2013;31:1063–84.CrossRefPubMed
6.
Lowes LE, Goodale D, Keeney M, Allan AL. Image cytometry analysis of circulating tumor cells. Methods Cell Biol. 2011;102:261–90.CrossRefPubMed
7.
Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–215.CrossRefPubMed
8.
Ignatiadis M, Riethdorf S, Bidard F-C, Vaucher I, Khazour M, Rothé F, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014;16:R43.CrossRefPubMedPubMedCentral
9.
Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med. 2014;2:108.PubMedPubMedCentral
10.
Harouaka R, Kang Z, Zheng S-Y, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. 2014;141:209–21.CrossRefPubMed
11.
Rodrıguez-Gonzalez FG, Mustafa DAM, Mostert B, Sieuwerts AM. The challenge of gene expression profiling in heterogeneous clinical samples. Methods San Diego Calif. 2013;59:47–58.CrossRef
12.
Ghersevich S, Ceballos MP. Mammaglobin A: review and clinical utility. Adv Clin Chem. 2014;64:241–68.CrossRefPubMed
13.
López-Muñoz E, Méndez-Montes M. Markers of circulating breast cancer cells. Adv Clin Chem. 2013;61:175–224.CrossRefPubMed
14.
15.
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5:179ra47.CrossRefPubMedPubMedCentral
16.
Aurilio G, Sciandivasci A, Munzone E, Sandri MT, Zorzino L, Cassatella MC, et al. Prognostic value of circulating tumor cells in primary and metastatic breast cancer. Expert Rev Anticancer Ther. 2012;12:203–14.CrossRefPubMed
17.
Lianidou ES, Markou A. Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med CCLM FESCC. 2011;49:1579–90.
18.
Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 2013;6:528–38.CrossRefPubMedPubMedCentral
19.
Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, et al. Circulating tumor cells in breast cancer. Clin Chim Acta Int J Clin Chem. 2013;423:39–45.CrossRef
20.
Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014;16:R23.CrossRefPubMedPubMedCentral
21.
Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med. 2014;2:109.PubMedPubMedCentral
22.
Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25:1506–16.CrossRef
23.
Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014;142:271–80.CrossRefPubMed
24.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.CrossRefPubMedPubMedCentral
25.
Martowicz A, Spizzo G, Gastl G, Untergasser G. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer. 2012;12:501.CrossRefPubMedPubMedCentral
26.
Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, et al. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer. 2011;11:45.CrossRefPubMedPubMedCentral
27.
Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:2821–5.
28.
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2593–600.CrossRef
29.
Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32:1073–81.CrossRefPubMed
30.
Li G, Zhang J, Jin K, He K, Wang H, Lu H, et al. Human mammaglobin: a superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med. 2011;5:249–60.CrossRefPubMed
31.
Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.CrossRefPubMedPubMedCentral
32.
Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers. 2014;6:684–707.CrossRefPubMedPubMedCentral
33.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRefPubMed
34.
Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:891–7.CrossRef
35.
Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113:2422–30.CrossRefPubMed
36.
Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:5701–10.CrossRef
37.
Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15:406–14.CrossRefPubMed
38.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:1144–50.CrossRef
39.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13:R67.CrossRefPubMedPubMedCentral
40.
Martín M, Custodio S, de Las Casas M-LM, García-Sáenz J-Á, de la Torre J-C, Bellón-Cano J-M, et al. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist. 2013;18:917–23.CrossRefPubMedPubMedCentral
41.
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:6403–9.CrossRef
42.
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3483–9.CrossRef
43.
Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32:179–88.CrossRefPubMed
44.
Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688–95.CrossRefPubMed
45.
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16:2634–45.CrossRef
46.
Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol. 2010;17:1539–45.CrossRefPubMed
47.
Bidard F-C, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21:729–33.CrossRef
48.
Biggers B, Knox S, Grant M, Kuhn J, Nemunatitis J, Fisher T, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol. 2009;16:969–71.CrossRefPubMed
49.
Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106:dju066.CrossRefPubMedPubMedCentral
50.
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:4414–22.CrossRef
51.
Pierga J-Y, Petit T, Lévy C, Ferrero J-M, Campone M, Gligorov J, et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:1298–304.CrossRef
52.
Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7004–10.CrossRef
53.
Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA. 2004;101:9393–8.CrossRefPubMedPubMedCentral
54.
Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:1744–50.CrossRef
55.
Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15:1164–8.CrossRefPubMedPubMedCentral
56.
57.
Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000;2:400–7.CrossRefPubMedPubMedCentral
58.
59.
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE. 2012;7:e33788.CrossRefPubMedPubMedCentral
60.
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:3997–4013.CrossRef
Metadata
Title
Review: circulating tumor cells in the practice of breast cancer oncology
Authors
R. Ramos-Medina
F. Moreno
S. Lopez-Tarruella
M. del Monte-Millán
I. Márquez-Rodas
E. Durán
Y. Jerez
J. A. Garcia-Saenz
I. Ocaña
S. Andrés
T. Massarrah
M. González-Rivera
M. Martin
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1460-2

Other articles of this Issue 8/2016

Clinical and Translational Oncology 8/2016 Go to the issue

Brief Research Article

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

Review Article

Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases

Research Article

Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance

Research Article

Pin1 promotes prostate cancer cell proliferation and migration through activation of Wnt/β-catenin signaling

Research Article

Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer

Research Article

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits